Key result
SGLT2 inhibitors reduced the composite outcome of cardiovascular death or first hospitalization for heart failure by 20% (HR 0.80) in patients with HFpEF.
Why the study?
HFpEF represents nearly half of HF cases in developed countries, but its pathophysiology is complex and little understood, and its variety of phenotypes complicates diagnosis and treatment.
This review discusses recent clinical trials and new perspectives on the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF).
Hypothesis-generating for HFpEF phenotypes and diagnosis; prospective trials needed before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Saraiva et al. (2022) conducted a review in Heart failure with preserved ejection fraction (HFpEF) (n=12,251). SGLT2 inhibitors vs. Placebo was evaluated on Composite outcome of cardiovascular death or first hospitalization for HF (HR 0.80, 95% CI 0.73-0.87). SGLT2 inhibitors reduced the composite outcome of cardiovascular death or first hospitalization for heart failure by 20% (HR 0.80) in patients with HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: